TRC105 was therefore studied in combination with VEGF inhibitors in glioblastoma [66], sarcoma [67,68], RCC [69,70], breast cancer [71], metastatic castration-resistant prostate cancer [48,72], hepatocellular carcinoma [73,74] and urothelial carcinoma [75]. This evidence concerns the gene VEGFA and breast cancer.